Literature DB >> 12057899

Endometrial and colorectal tumors from patients with hereditary nonpolyposis colon cancer display different patterns of microsatellite instability.

Shannon A Kuismanen1, Anu-Liisa Moisio, Pascal Schweizer, Kaspar Truninger, Reijo Salovaara, Johanna Arola, Ralf Butzow, Josef Jiricny, Minna Nyström-Lahti, Päivi Peltomäki.   

Abstract

The colorectum and uterine endometrium are the two most commonly affected organs in hereditary nonpolyposis colon cancer (HNPCC), but the genetic basis of organ selection is poorly understood. As tumorigenesis in HNPCC is driven by deficient DNA mismatch repair (MMR), we compared its typical consequence, instability at microsatellite sequences, in colorectal and endometrial cancers from patients with identical predisposing mutations in the MMR genes MLH1 or MSH2. Analysis of non-coding (BAT25, BAT26, and BAT40) and coding mononucleotide repeats (MSH6, MSH3, MLH3, BAX, IGF2R, TGF beta RII, and PTEN), as well as MLH1- and MSH2-linked dinucleotide repeats (D3S1611 and CA7) revealed significant differences, both quantitative and qualitative, between the two tumor types. Whereas colorectal cancers displayed a predominant pattern consisting of instability at the BAT loci (in 89% of tumors), TGF beta RII (73%), dinucleotide repeats (70%), MSH3 (43%), and BAX (30%), no such single pattern was discernible in endometrial cancers. Instead, the pattern was more heterogeneous and involved a lower proportion of unstable markers per tumor (mean 0.27 for endometrial cancers versus 0.45 for colorectal cancers, P < 0.001) and shorter allelic shifts for BAT markers (average 5.1 bp for unstable endometrial cancers versus 9.3 bp for colorectal cancers, P < 0.001). Among the individual putative "target" loci, PTEN instability was associated with endometrial cancers and TGF beta RII instability with colon cancers. The different instability profiles in endometrial and colorectal cancers despite identical genetic predisposition underlines organ-specific differences that may be important determinants of the HNPCC tumor spectrum.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12057899      PMCID: PMC1850838          DOI: 10.1016/S0002-9440(10)61144-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  44 in total

1.  Familial endometrial cancer in female carriers of MSH6 germline mutations.

Authors:  J Wijnen; W de Leeuw; H Vasen; H van der Klift; P Møller; A Stormorken; H Meijers-Heijboer; D Lindhout; F Menko; S Vossen; G Möslein; C Tops; A Bröcker-Vriends; Y Wu; R Hofstra; R Sijmons; C Cornelisse; H Morreau; R Fodde
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

2.  Lack of MSH2 and MSH6 characterizes endometrial but not colon carcinomas in hereditary nonpolyposis colorectal cancer.

Authors:  P Schweizer; A L Moisio; S A Kuismanen; K Truninger; R Vierumäki; R Salovaara; J Arola; R Butzow; J Jiricny; P Peltomäki; M Nyström-Lahti
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

Review 3.  A mutator phenotype in cancer.

Authors:  L A Loeb
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

4.  Mutations associated with microsatellite unstable colorectal carcinomas exhibit widespread intratumoral heterogeneity.

Authors:  R Barnetson; J Jass; R Tse; R Eckstein; B Robinson; M Schnitzler
Journal:  Genes Chromosomes Cancer       Date:  2000-10       Impact factor: 5.006

5.  Genomic instability and target gene mutations in colon cancers with different degrees of allelic shifts.

Authors:  A Percesepe; M Pedroni; E Sala; M Menigatti; F Borghi; L Losi; A Viel; M Genuardi; P Benatti; L Roncucci; P Peltomäki; M Ponz de Leon
Journal:  Genes Chromosomes Cancer       Date:  2000-04       Impact factor: 5.006

6.  Frequent frameshift mutations of RIZ in sporadic gastrointestinal and endometrial carcinomas with microsatellite instability.

Authors:  Z Piao; W Fang; S Malkhosyan; H Kim; A Horii; M Perucho; S Huang
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

7.  Molecular pathologic analysis enhances the diagnosis and management of Muir-Torre syndrome and gives insight into its underlying molecular pathogenesis.

Authors:  M C Southey; M A Young; J Whitty; S Mifsud; M Keilar; L Mead; L Trute; K Aittomäki; S A McLachlan; H Debinski; D J Venter; J E Armes
Journal:  Am J Surg Pathol       Date:  2001-07       Impact factor: 6.394

8.  Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.

Authors:  G L Mutter; M C Lin; J T Fitzgerald; J B Kum; J P Baak; J A Lees; L P Weng; C Eng
Journal:  J Natl Cancer Inst       Date:  2000-06-07       Impact factor: 13.506

9.  The role of hypermethylation of the hMLH1 promoter region in HNPCC versus MSI+ sporadic colorectal cancers.

Authors:  J M Wheeler; A Loukola; L A Aaltonen; N J Mortensen; W F Bodmer
Journal:  J Med Genet       Date:  2000-08       Impact factor: 6.318

10.  Absence of PTEN repeat tract mutation in endometrial cancers with microsatellite instability.

Authors:  D E Cohn; J B Basil; A R Venegoni; D G Mutch; J S Rader; T J Herzog; D J Gersell; P J Goodfellow
Journal:  Gynecol Oncol       Date:  2000-10       Impact factor: 5.482

View more
  37 in total

1.  The landscape of microsatellite instability in colorectal and endometrial cancer genomes.

Authors:  Tae-Min Kim; Peter W Laird; Peter J Park
Journal:  Cell       Date:  2013-11-07       Impact factor: 41.582

2.  Differential roles of EPS8 in carcinogenesis: loss of protein expression in a subset of colorectal carcinoma and adenoma.

Authors:  Wael M Abdel-Rahman; Salla Ruosaari; Sakari Knuutila; Päivi Peltomäki
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

Review 3.  Laboratory Assays in Evaluation of Lynch Syndrome in Patients with Endometrial Carcinoma.

Authors:  Bojana Djordjevic; Russell R Broaddus
Journal:  Surg Pathol Clin       Date:  2016-04-11

Review 4.  Role of the clinical pathology laboratory in the evaluation of endometrial carcinomas for Lynch syndrome.

Authors:  Bojana Djordjevic; Russell R Broaddus
Journal:  Semin Diagn Pathol       Date:  2014-04-02       Impact factor: 3.464

Review 5.  Importance of PCR-based Tumor Testing in the Evaluation of Lynch Syndrome-associated Endometrial Cancer.

Authors:  Amanda S Bruegl; Annessa Kernberg; Russell R Broaddus
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

6.  Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer.

Authors:  Amanda S Bruegl; Bojana Djordjevic; Brittany Batte; Molly Daniels; Bryan Fellman; Diana Urbauer; Rajyalakshmi Luthra; Charlotte Sun; Karen H Lu; Russell R Broaddus
Journal:  Cancer Prev Res (Phila)       Date:  2014-04-25

7.  Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation.

Authors:  Sridharan Gururangan; Wendy Frankel; Russell Broaddus; Mark Clendenning; Leigha Senter; Marie McDonald; James Eastwood; David Reardon; James Vredenburgh; Jennifer Quinn; Henry S Friedman
Journal:  Neuro Oncol       Date:  2007-11-09       Impact factor: 12.300

8.  Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers.

Authors:  Paul J Goodfellow; Barbara M Buttin; Thomas J Herzog; Janet S Rader; Randall K Gibb; Elizabeth Swisher; Katherine Look; Ken C Walls; Ming-Yu Fan; David G Mutch
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

9.  Clinical Challenges Associated with Universal Screening for Lynch Syndrome-Associated Endometrial Cancer.

Authors:  Amanda S Bruegl; Kari L Ring; Molly Daniels; Bryan M Fellman; Diana L Urbauer; Russell R Broaddus
Journal:  Cancer Prev Res (Phila)       Date:  2016-12-13

Review 10.  Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.

Authors:  Henry T Lynch; Murray Joseph Casey; Carrie L Snyder; Chhanda Bewtra; Jane F Lynch; Matthew Butts; Andrew K Godwin
Journal:  Mol Oncol       Date:  2009-02-21       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.